| Identification | Back Directory | [Name]
Benzoic acid, 4-[1-[[[(5R)-6-[[4-(trifluoromethyl)phenyl]methyl]-6-azaspiro[2.5]oct-5-yl]carbonyl]amino]cyclopropyl]- | [CAS]
2502965-92-4 | [Synonyms]
Benzoic acid, 4-[1-[[[(5R)-6-[[4-(trifluoromethyl)phenyl]methyl]-6-azaspiro[2.5]oct-5-yl]carbonyl]amino]cyclopropyl]- | [Molecular Formula]
C26H27F3N2O3 | [MOL File]
2502965-92-4.mol | [Molecular Weight]
472.5 |
| Hazard Information | Back Directory | [Uses]
(R)-Vorbipiprant ((R)-CR6086) is an orally active antagonist for prostaglandin E2 receptor 4 (EP4) with Ki of 16.6 nM for human EP4. (R)-Vorbipiprant inhibits PGE2 (HY-101952)-induced cAMP production with an IC50 of 22 nM. (R)-Vorbipiprant exhibits immunomodulatory and anti-angiogenic activities, and ameliorates the collagen-induced arthritis in mice[1]. | [IC 50]
hEP4: 16.6 nM (Ki) | [References]
[1] Caselli G, et al., Pharmacological characterisation of CR6086, a potent prostaglandin E2 receptor 4 antagonist, as a new potential disease-modifying anti-rheumatic drug. Arthritis Res Ther. 2018 Mar 1;20(1):39. DOI:10.1186/s13075-018-1537-8 |
|
|